Clinical trials on treatment and prevention of ischemic stroke in SCD patients
| Clinical trial . | Description/outcome . |
|---|---|
| STOP 1 (Stroke Prevention Trial in Sickle Cell Anemia)52 | Children with abnormal TCD velocities who received long-term chronic transfusion to maintain HbS. |
| STOP 2 Trial 53 | Discontinuing chronic transfusion in children with normalized TCD led to increased rate of abnormal TCD conversion and stroke. Therefore, the trial recommends continuing transfusion therapy even after TCD velocities are normal. |
| TWiTCH (TCD With Transfusions Changing to Hydroxyurea)9 | Hydroxyurea is noninferior to transfusion for primary stroke prevention in children without cerebral vasculopathy or prior history of TIA who have received transfusion for at least 1 year. The optimal duration of transfusion prior to switching to hydroxyurea has not been established. |
| SWiTCH (Stroke With Transfusion Changing to Hydroxyurea)54 | Transfusion therapy is more effective than hydroxyurea in reducing secondary stroke in children. The trial closed early because approximately 10% of the patients treated with hydroxyurea/phlebotomy experienced a second stroke vs patients receiving chronic transfusion therapy. |
| SIT (Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial)7 | Children with silent cerebral infarcts and normal or conditional TCD velocities who received chronic transfusion and maintained HbS. |
| Clinical trial . | Description/outcome . |
|---|---|
| STOP 1 (Stroke Prevention Trial in Sickle Cell Anemia)52 | Children with abnormal TCD velocities who received long-term chronic transfusion to maintain HbS. |
| STOP 2 Trial 53 | Discontinuing chronic transfusion in children with normalized TCD led to increased rate of abnormal TCD conversion and stroke. Therefore, the trial recommends continuing transfusion therapy even after TCD velocities are normal. |
| TWiTCH (TCD With Transfusions Changing to Hydroxyurea)9 | Hydroxyurea is noninferior to transfusion for primary stroke prevention in children without cerebral vasculopathy or prior history of TIA who have received transfusion for at least 1 year. The optimal duration of transfusion prior to switching to hydroxyurea has not been established. |
| SWiTCH (Stroke With Transfusion Changing to Hydroxyurea)54 | Transfusion therapy is more effective than hydroxyurea in reducing secondary stroke in children. The trial closed early because approximately 10% of the patients treated with hydroxyurea/phlebotomy experienced a second stroke vs patients receiving chronic transfusion therapy. |
| SIT (Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial)7 | Children with silent cerebral infarcts and normal or conditional TCD velocities who received chronic transfusion and maintained HbS. |